Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5223]

Advances in personalised medicine

Advances in personalised medicine

ASCO 2014: PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma

ASCO 2014: PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma

ASCO 2014: Ipilimumab with nivolumab achieves long-term survival in advanced melanoma

ASCO 2014: Ipilimumab with nivolumab achieves long-term survival in advanced melanoma

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in...

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast...

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced differentiated thyroid cancer

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced...

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent...

New approach for tackling drug resistance in AML

New approach for tackling drug resistance in AML

Mapping the human proteome

Mapping the human proteome

More from ecancer